Hepatitis B vaccine efficacy in patients with chronic liver disease by hepatitis C virus

Arquivos de Gastroenterologia

Volumn 41, Issue 3, 2004, Pages 180-184

  De Mattos, Angela Alves ^a,b   Gomes, Eliana Buksztejn ^a   Tovo, Cristiane Valle ^a   Alexandre, Claúdio Osmar Pereira ^a   Remião, José Oscar Dos Reis ^a  

^a UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

^b NONE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS B ANTIBODY; RECOMBINANT HEPATITIS B VACCINE; VIRUS RNA;

ADULT; AGED; ARTICLE; CHRONIC LIVER DISEASE; CONTROLLED STUDY; DNA SEQUENCE; DOSE RESPONSE; DRUG EFFICACY; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNE DEFICIENCY; LIVER CIRRHOSIS; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; POLYMERASE CHAIN REACTION; PROSPECTIVE STUDY; SEROCONVERSION; TREATMENT OUTCOME; VACCINATION; VIRUS LOAD;

EID: 11144273185     PISSN: 00042803     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0004-28032004000300008     Document Type: Article

References (40)

1. Averhoff F, Mahoney F, Coleman P, Scjatz G, Hurwitz E, Margocis H. Immunogenicity of hepatitis B vaccines, implications for personal at occupacional risk of hepatitis B virus infection. Am J Prev Med 1998;15:1-8.
2. Awofeso N, Levy M, Harper S, Jones M, Hayes M, Douglas J, Fisher M, Folpp D. Response to HBV vaccine in relation to vaccine dose and anti-HCV positivity: a new South Wales correctional facilities. Vaccine 2001;19:4245.
3. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic C. Hepatology 1996;24:289-93.
4. Bennet RG, Powers DC, Remsburg RE, Scheve A, Clements ML. Hepatitis B virus vaccination for older adults. J Am Geriatr Soc 1996;44:699-703.
5. Berner J, Kadian M, Post J, Muller C, Schwarte M, Conn M, Borcich A. Prophylactic recombinant hepatitis B vaccine in patients undergoing orthotopic liver transplantation. Transplant Proc 1993;25:1751-2.
6. Bosch FX, Ribes J, Borràs J. Epidemiology of primary liver cancer. Semin Liver Dis 1999;19:271-85.
7. Centers for Disease Control. Recommendations of the Advisory Committee on Prevention of hepatitis. A through active or passive Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 1996;455:1-30.
8. Chalasani N, Smallwood G, Halcomb J, Fried MW, Boyer TD. Is vaccination against hepatitis B infection indicated in patients waiting for or after orthotopic liver transplantation?. Liver Transpl Surg 1998;4:128-32.
9. Chiba T, Matsuzaki Y, Abei M. The role of previous hepatitis B virus infection and heavy smoking in hepatitis C virus-related hepatocellular carcinoma. Am J Gastroenterol 1996;91:1195-203.
10. Clemens SAC, Fonseca JC, Azevedo T, Cavalcanti A, Silveira TR, Castilho MC, Clemens R. Soroprevalência para hepatite A e hepatite B em quatro centres do Brasil. Rev Soc Bras Med Trop 2000;33:1-10.
11. EASL International Consensus Conference on Hepatitis C. Paris, 26-28 February 1999. Consensus statement. J Hepatol 1999;30:956-61.
12. Eddleston A. Modern vaccines - hepatitis. Lancet 1990;335:1142-5.
13. Fang JWS, Albrecht JK, Jacobs S, Lau JY. Quantification of serum hepatitis C virus RNA. Hepatology 1999;29:997-8.
14. Ilan Y, Ashuv Y, Tur-Kaspa R, Shou Ual D. Chronic hepatitis C virus infection with exposure to hepatitis B virus. Isr J Med Sci 1994;30:259-63.
15. Kamel M, El Maniaiawi M, Miller FD. Recombinant hepatitis B vaccine immunogenicity in presence of hepatitis C virus seropositivity. Lancet 1994;343:552 (letter).
16. Kane MA. Global status os hepatitis B immunization - commentary. Lancet 1996;348:696.
17. Katkov WN, Dienstag JL. Prevention and therapy of viral hepatitis. Semin Liver Dis 1991;11:165-74.
18. Keeffe EB, Iwarson S, Mcmahon BJ, Lindsay KL, Koff RS, Manns M, Bauncarten R, Wiese M, Fourneau M, Safary A, Klemens R, Krause DS. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology 1998;27:881-6.
19. Lee SD, Chan CY, Yu MI, Wang YJ, Chang FY, Lo KJ, Safary A. Safety and immunogenicity of inactived hepatitis A vaccine in patients with chronic liver disease. J Med Virol 1997;52:215-18
20. Lee SD, Chan CY, Yu MI, Lu RH, Chang FY, Lo KJ. Hepatitis B vaccination in patients with chronic hepatitis C. J. Med Virol 1999;59:463-468.
21. Lemon SM And Thomas DL. Vaccines to prevent viral hepatitis. N Engl J Med 1997;336:196-204.
22. Loinaz C, Juanes JR, Gonzales EM. Hepatitis B vaccination results in 140 liver transplant recipients. Hepatogastroenterology 1997;44:235-8.
23. Marsano LS, West DJ, Chan I, Hesley TM, Cox J, Hackworth V, Greenberg RN. A two-dose hepatitis B vaccine regimen: proof of priming and memory responses in young adults. Vaccine 1998;16:624-9.
24. Martinot-Peignoux M, Boyer N, L E Bretan V, Le guludec G, Castenau C, Akremi R, Marcellin P. A new step toward standardization of serum hepatitis C virus DNA quantification in patients with chronic hepatitis C. Hepatology 2000;31:726-9.
25. Mc Hutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, Goodman ZD, Ling MH, Cort S, Albrecht JK. Interferon alfa - 2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998;339:1485-92.
26. NlH. National Institute of Health consensus development conference panel statement: management of hepatitis C. Hepatology 1997;26(suppl 1)2S-10S.
27. Poynard T, Marcellin P, Lee SS, Niederau C, Minuck GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J. Randomized trial of interferon 2b plus ribavirin for 48 weeks or for 24 weeks versus interferon 2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998;352:1426-32.
28. Pugh RWH, Murray-Lyon IM, Dawson JL. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1983;60:646-9.
29. Roome AJ, Walsh SJ, Cartter ML, Hadler JL. Hepatitis B vaccine responsiveness in Connecticut public safety personnel. JAMA 1993;270:2931-4.
30. Rosman AS, Basu P, Galvin K, Lieber CS. Efficacy of a high and accelerated dose of hepatitis B vaccine in alcoholic patients: a randomized clinical trial. Am J Med 1997;103:217-22.
31. Roudot-Thraval F, Bastie A, Pawlotsky JM, Dhumeaux D. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: A French survey of 6,664 patients. Hepatology 1997;26:485-490.
32. Sagnelli E, Coppola N, Marrooco C. Acute hepatitis B in HCV chronic carriers: virological interaction on clinical course. Hepatology 2001;34:314 A.
33. Siddiqui F, Mutchnick M, Kinzie J, Peleman R, Naylor P, Ehrinpreis M. Prevalence of hepatitis A virus and hepatitis B virus immunity in patients with polymerase chain reaction-confirmed Hepatitis C: implications for vaccination strategy. Am J Gastroenterol 2001;96:858-63.
34. Van Thiel DH, El-Ashmawy L, Love K, Gavaler JS, Starzl TE. Response to hepatitis B vaccination by liver transplant candidates. Dig Dis Sci 1992;37:1245-49.
35. Van Thiel DH & Gavaler JS. Response to HBV vaccination in patients with severe liver disease. Absense of an HLA effect. Dig Dis Sci 1992;37:1447-51.
36. Van Thiel DH. Vaccination of patients with liver disease: who, when, and how. Liver Transpl Surg 1998;4:185-7.
37. Vento S, Garofano T, Renzini C, Cainelli F, Casali F, Ghironzi G, Ferraro T, Concia E. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998;338:286-90.
38. Wiedmann M, Liebert UG, Oesen U, Porst H, Wiese M, Schroeder S, Halm U, Mossner J, Berr F. Decreased immunogenicity of recombinant hepatitis B vacine in chronic hepatitis C. Hepatology 2000;31:230-4.
39. Wong V, Wreghitt TG, Alexander GJ. Prospective study of hepatitis B vaccination in patients with chronic hepatitis C. BMJ 1996;312:1336-7.
40. Wood RC, Macdonald KL, White KE, Hedberg CW, Hanson M, Osterholm MT. Risk factors for lack of detectable antibody following hepatitis B vaccination of Minnesota health care workers. JAMA 1993;270:2935-9.